Search

Improving healthcare quality while reducing costs is a goal Abt Global has been helping the Centers for Medicare and Medicaid Services (CMS) pursue for more than a decade through evaluations and more. CMS’s Integrated Care for Kids (InCK) payment and…

Be it outbreak, epidemic, or pandemic—human or zoonotic—the goal is to get reliable information on infectious diseases, quickly. Abt experts Laura Edwards and Sung-Woo Cho discuss strategies for harnessing machine learning and data visualization to provide actionable information—at scale—that can help stem a health crisis.

More than 2.3 million households participate in the U.S. Department of Housing and Urban Development’s (HUD) Housing Choice Voucher program, and almost a million of these households are comprised of families with children. With these vouchers, families…

The Centers for Medicare & Medicaid Services (CMS) developed the ACO Investment Model (AIM) to improve health care delivery in rural and underserved areas. AIM provided up-front payments to ACOs participating in Medicare’s Shared Savings Program (SSP)…

Understanding the intricate dynamics of pathogens and vectors is crucial to furthering effective disease research. Infectious and vector-borne diseases like COVID-19, influenza, malaria, dengue, tuberculosis, and HIV present daily challenges to health systems and community resilience around the world. Abt Global counters these threats to our shared global health security through evidence-based prevention and containment, groundbreaking disease detection and surveillance, and total health-system surge and recovery response stewarded by local government and community leaders. Through a One Health approach, we aim to help our partners build resilient, secure, and sustainable health systems that will allow their communities to thrive for generations.

Communities continue to face challenges accessing quality behavioral health care and services. Abt helps SAMHSA advance behavioral health excellence 

The Centers for Medicare & Medicaid Services created the Cell and Gene Therapy Access Model to be able to negotiate with manufacturers on behalf of states to make high-cost specialty drugs available to beneficiaries and affordable to State Medicaid Agencies.